develop in Medical Technology

Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences

CORK, Ireland, July 16 /PRNewswire/ --Tibotec Pharmaceuticals today announced that it has entered into a license and collaboration agreement with Gilead Sciences, Inc. for the development and commercialization of a new once-daily fixed-dose antiretroviral product containing Tibotec's inv...

Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System

New Capabilities Will Further Extend GeneXpert System Technology Advantages SUNNYVALE, Calif., June 10 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD ) today announced that it has received a notice of grant award from the National Institute of Allergy and Infectious Diseases to develop new...

Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease

MORGANTOWN, W.Va., May 27 /PRNewswire-USNewswire/ -- The Blanchette Rockefeller Neurosciences Institute (BRNI) and Inverness Medical Innovations, Inc. (Inverness, NYSE: IMA ) of Waltham, Massachusetts, a global leader in rapid diagnostics and health management, announced today that they will work...

Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

OXFORD, England, May 18 /PRNewswire/ -- - New Alliance a Key Step for OBT to Broaden its Exciting Pipeline of Therapeutic Antibodies Oxford BioTherapeutics (OBT) today announced a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic an...

Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly

Companies Committed to Investing in New Product Presentations for Patients SAN DIEGO and INDIANAPOLIS, April 29 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) today announced that the companies have agreed in principle to the ...

ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent

FREDERICK, Md., April 21 /PRNewswire/ -- ImQuest BioSciences and Arisyn Therapeutics jointly announced today the successful acquisition of funding from the National Institutes of Health to support the development of novel small molecule therapeutics for the treatment of hepatitis C virus (HCV) inf...

MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer

WOONSOCKET, R.I., March 19 /PRNewswire-FirstCall/ --MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announced today that it has entered into a cooperative research and development agreement with Maxim Biotech, Inc. to develop products for the study of liver stem cells and liver cancer. ...

Certification Commission for Healthcare Information Technology to Develop Dermatology-Specific Functionality Criteria for Electronic Health Record (EHR) Technology

New Criteria to Help Facilitate EHR Adoption in Small, Ambulatory Physician Practices SCHAUMBURG, Ill., March 3 /PRNewswire-USNewswire/ -- The Certification Commission for Healthcare Information Technology (CCHIT(R)), the federally recognized body for testing and certifying electronic healt...

Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments

CHADDS FORD, Pa., Feb. 10 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that it has signed two research collaboration agreements to develop novel treatments for pain and to discover potential treatments for cancer. The first collaboration, with Harvar...

U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant

SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that the Naval Medical Research Center (NMRC) plans to conduct preclinical and Phase 1 evaluation of a dengue DNA vaccine formulated with the company's Vaxfectin(R) adjuvant and delivered with the Bio...

InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer

BILTHOVEN and AMSTERDAM, The Netherlands, October 30 /PRNewswire/ -- InteRNA Technologies B.V. and VU university medical center in Amsterdam, VUmc, announce today the signing of a framework research agreement to develop microRNA (miRNA)-based diagnostics and therapeutics for cancer using InteR...

Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation

STOCKHOLM, October 2 /PRNewswire/ -- Athera Biotechnologies AB and Dyax Corp. (NASDAQ: DYAX ) announced today that they have entered into a collaboration to discover and to develop therapeutic products for the prevention or treatment of cardiovascular inflammatory diseases. The collaboration...

Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering

LEXINGTON, Mass., Sept. 26 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that it has signed a development, license and commercialization agreement with Teva Pharmaceutical Industries Ltd. for the exclusive, worldwide rights to pagoclone. Indevus previously anno...

AMT Obtains License to Amgen's GDNF Gene to Develop Treatment for Parkinson's Disease with AMT's Proprietary Gene Therapy Platform

AMSTERDAM, The Netherlands, September 18 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from Amgen to use their GDNF gene for the development of a gene therapy treatment for Par...

Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer

BRIDGEWATER, N.J., and BRUSSELS, Belgium, Sept. 15 /PRNewswire/ -- Drais Pharmaceuticals, Inc. and Unibioscreen S.A. today announced that they have entered into a global agreement to develop and commercialize UNBS 5162, one of Unibioscreen's investigational drug and potential breakthrough trea...

Researchers at Axial Biotech Develop a DNA Test for Scoliosis

Study results presented at the Scoliosis Research Society Meeting in Salt Lake City SALT LAKE CITY, Sept. 11 /PRNewswire/ -- Researchers at Axial Biotech, Inc., announced today that they have identified specific genetic markers for scoliosis. The data from this res...

AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds

SINGAPORE, Aug. 15 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN ) today announced an innovative new partnership with the National Cancer Centre Singapore (NCCS) and the National University Hospital (NUH) to develop anti-cancer compounds. The collaboration, which is spelt out in a Memorand...

ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide

FREDERICK, Md., July 29 /PRNewswire/ -- ImQuest BioSciences announced today the successful acquisition of funding from the National Institute of Allergy and Infectious Disease (NIAID/NIH) to support the development of pyrimidinedione inhibitors as topical microbicides to prevent the sexual tra...

Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer

Collaboration Will Seek to Identify Unique microRNA Signatures That Will Predict Risk of Recurrence in Lung Cancer Patients The Project Will Leverage Rosetta Genomics' Proprietary microRNA Extraction and Quantification Technologies, and M. D. Anderson's Extensive Know-How ...

Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies

- Results from Gene Identification Studies Presented at ASCO Support Further Exploration of Possible Tests to Predict Response to Targeted Therapies for Colon and Breast Cancers - REDWOOD CITY, Calif., May 31 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ), ...

UPDATE: Infant Primates Given Vaccines on U.S. Children's Immunization Schedule Develop Behavioral Symptoms of Autism

GROUNDBREAKING RESEARCH PROVIDES EVEN MORE SCIENCE SUPPORTING THE THEORY THAT VACCINES CAN AND DO CAUSE AUTISM NIXA, Mo., May 19 /PRNewswire-USNewswire/ -- A primate model for autism using the U.S. children's immunization schedule was unveiled at the International Meeting For Autism Resear...

Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454

-Memory Receives $6 Million Milestone Payment- -Memory to Host Conference Call at 9:00 a.m. EDT Today- MONTVALE, N.J. and BASEL, Switzerland, May 2 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) and Roche (SWX: ROG) today announced that Roche has ex...

Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases

NESS ZIONA, Israel and SOPHIA-ANTIPOLIS, France, April 29 /PRNewswire/ -- Foamix Ltd, a global leader in the development of dermatological foam medications and Galderma, a worldwide specialty pharmaceutical company focused on dermatology, today announced that they have signed an agreement to d...

Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Company's MicroRNA Technology

Tests Will be Developed and Validated Clinically at Clinical Laboratory Improvement Amendments (CLIA) Certified Laboratory at the University of California, Irvine School of Medicine Rosetta Genomics Expects Three Tests Applying its MicroRNA Technology to be Developed and...

Velos to Develop Key System Interface for Clinical Research

- Will facilitate tight integration between sponsors and investigators - FREMONT, Calif., March 26 /PRNewswire/ -- Velos, Inc., a recognized leader and trusted resource for clinical trial management information systems and member of the Oracle PartnerNetwork, will work to develop a key interfa...

Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease

EMERYVILLE and NOVATO, Calif., March 3 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII ) and the Buck Institute for Age Research (Buck) announced today they have entered into a collaboration and exclusive license agreement to develop a novel therapy for Alzheimer's ...

Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody

INCHEON, South Korea, Jan. 10 /PRNewswire/ -- Celltrion, Inc., a Korean biopharmaceutical company whose core business is currently contract manufacturing, and CSL Limited, Australia's leading biopharmaceutical company, announced today the signing of an agreement for the development and supply ...

Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug

SAN JOSE, Calif., Jan. 7 /PRNewswire/ -- Tacere Therapeutics, Inc., an RNA interference (RNAi)-based therapeutics developer, announced today that it has entered into a collaboration and license agreement with Pfizer Inc. to develop and commercialize its Hepatitis C virus (HCV) compound, TT-033...

GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution

* Collaboration aimed at enabling vaccine production facility commissioning in half the time of a traditional egg-based facility. * Once established, such a vaccine facility could allow manufacturing of pandemic flu vaccine to commence within 12 weeks of the strain isolation CHALFONT...

Raydiance Collaborates With Rutgers University and Nation's Largest Tissue Bank to Develop Innovative Tissue Processing Approaches

Scientists Leveraging Precision and Power of Raydiance USP Laser Platform to Separate Skin Layers Without Collateral Damage; Decontaminate Tissue; Speed Tissue Cleaning Initial Proof of Concept Testing Successful During Feasibility Trials PETALUMA, Calif. and NEW BR...

Researchers Develop New Procedure to Screen All 46 Human Chromosomes to Identify Abnormalities in Embryos

New technology developed by researchers at Reproductive Medicine Associates of New Jersey awarded General Program Prize Paper at American Society for Reproductive Medicine Annual Meeting WASHINGTON and MORRISTOWN, N.J., Oct. 18 /PRNewswire/ -- Researchers at Reproductive Medici...

Surgeons Develop Innovative Life-Saving Treatments to Correct Massive Bleeding in Trauma Patients

NEW ORLEANS, Oct. 9 /PRNewswire-USNewswire/ -- Surgeons are testing new ways of treating the number-one cause of death from trauma in this country -- massive bleeding. Investigators from Massachusetts General Hospital, Boston, are deeply cooling the entire body to prolong the time surgeons hav...

Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors

PORTLAND, Ore., Oct. 3 /PRNewswire/ -- Virogenomics, Inc. today announced that the company has been awarded a $2 million grant from the National Institute of Standards and Technology (NIST) to develop a Sensor System on Panel (SSOP) that tests for many different biological markers in a single ...

Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Company's Anthrax Therapeutic

PINE BROOK, N.J., Sept. 25 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced it has been awarded a contract for $12 million for advanced d...

Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza

SUNNYVALE, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced the termination of its contract with the Centers for Disease Control and Prevention (CDC) for development of a rapid point-of-care diagnostic to detect influenza viruses A and B, and the H5N1 "Avian In...

U. of Md. Researchers to Develop Devices to Revolutionize Drug Research

COLLEGE PARK, Md., Sept. 18 /PRNewswire-USNewswire/ --- A multi-disciplinary group of researchers from the University of Maryland, College Park, and the University of Maryland Biotechnology Institute (UMBI) has won a competitive, $2 million National Science Foundation (NSF) grant to revolution...

LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies

BOZEMAN, Mont., Sept. 18 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc., today announced a strategic partnership with Biogen Idec (Nasdaq: BIIB) to develop therapies targeting CD103 for the treatment of chronic inflammatory diseases including potential respiratory, gastrointestinal, and autoim...

Saving Lives of Florida Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment

Tallahassee Dermatologist Encourages Regular Skin Examinations TALLAHASSEE, Fla., Sept. 12 /PRNewswire/ -- Once every two hours a Florida resident is diagnosed with a new case of melanoma skin cancer, according to the American Cancer Society. A local dermatologist is working to decrease t...

S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies

SINGAPORE, Sept. 11 /PRNewswire/ -- S*BIO Pte Ltd today announced the development of a novel and proprietary orally-administered compound, SB1518, for the treatment of myeloproliferative disorders (MPD) and certain hematological malignancies. MPD is believed to be caused by a specific mutation...

Saving Lives of California Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment

San Diego Dermatologist Promoting Regular Skin Examinations SAN DIEGO, Aug. 27 /PRNewswire/ -- Once every ninety minutes a California resident is diagnosed with a new case of melanoma skin cancer, according to the American Cancer Society. A local dermatologist is working to decrease this...